Dianthus raised a $100M Series A in April 2022, which is being used to expand leadership and scientific teams, advance the company’s lead program, DNTH103, and to accelerate additional discovery pipeline programs for people living with severe and rare autoimmune diseases.

DNTH103 is a potent, next-generation monoclonal antibody that selectively targets the active form of complement C1s.